Preladenant （previously known as SCH-420814） is an antagonist for adenosine A2A receptor with high affinity （Ki of 1.1 nM in vitro） and selectivity （＞1000-fold over other adenosine receptos.
It was initially developed by Schering-Plough as a potential treatment for Parkinson's disease.
This Biotin-d（PEG）2-Preladenant conjugate was designed with a flexible PEG linker and synthesized at CellMosaic for our customer's usage of detecting and characterizing A2AR receptor.The final product is supplied as a DMSO solution at 5 mg/mL.
The product is sold as 1 vial of 1 mg （Cat# CM61008-1MG）, 5 vials of 1 mg （Cat# CM61008-5MG）, and 10 vials of 1 mg （Cat# CM61008-10MG）.
